GLP-1 Drugs and the Shifting Landscape of Health Equity, Cost Control and Prescription Practices
In the dynamic landscape of modern healthcare, the surging demand for GLP-1 drugs is sparking heated debates around health equity, cost control, and prescription practices.
In a recent First Report Managed Care article, Julie Schulz, MD, MPH Avalon Vice President of Product, clearly articulates this emerging challenge:
"The overwhelming demand for GLP-1 drugs will pose a real test for health equity in 2025. Prescribing these medications for those who do not need them for diabetes and other indicated uses deprives patients with the greatest need. In the interest of equity—and to control costs—health plans and employers will begin using laboratory test values, such as A1c, lipids, kidney and liver function, to determine who truly needs GLP-1 medications."
Read the full article at First Report Managed Care.